Clarity is a global leader in Targeted Copper Theranostics (tct), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the “perfect pairing” of copper-64 (64Cu) and copper-67 (67Cu) for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market.
Clarity was incorporated on 8 April 2010 and is headquartered in Sydney, Australia and has subsidiaries in Belgium and the US. As it is a clinical stage company, Clarity does not currently generate any revenue.
It is anticipated that CU6 will list on the ASX during August 2021.
Be the first to comment